Literature DB >> 22854933

Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression.

Cristina Cusin, George Q Hilton, Andrew A Nierenberg, Maurizio Fava.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22854933     DOI: 10.1176/appi.ajp.2012.12020219

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  14 in total

Review 1.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 2.  Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Erica M Richards; Carlos A Zarate
Journal:  J Neural Transm (Vienna)       Date:  2013-12-08       Impact factor: 3.575

Review 3.  Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Authors:  Nicolas D Iadarola; Mark J Niciu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy B Lundin; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Ther Adv Chronic Dis       Date:  2015-05       Impact factor: 5.091

Review 4.  [Ketamine as antidepressant: the current study situation].

Authors:  P S Ritter; M Bauer; M Pilhatsch
Journal:  Nervenarzt       Date:  2014-11       Impact factor: 1.214

5.  Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases.

Authors:  Alana Iglewicz; Katherine Morrison; Richard A Nelesen; Tingting Zhan; Boris Iglewicz; Nathan Fairman; Jeremy M Hirst; Scott A Irwin
Journal:  Psychosomatics       Date:  2014-06-05       Impact factor: 2.386

Review 6.  Ketamine administration in depressive disorders: a systematic review and meta-analysis.

Authors:  Guillaume Fond; Anderson Loundou; Corentin Rabu; Alexandra Macgregor; Christophe Lançon; Marie Brittner; Jean-Arthur Micoulaud-Franchi; Raphaelle Richieri; Philippe Courtet; Mocrane Abbar; Matthieu Roger; Marion Leboyer; Laurent Boyer
Journal:  Psychopharmacology (Berl)       Date:  2014-07-20       Impact factor: 4.530

7.  Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.

Authors:  Kathryn R Cullen; Palistha Amatya; Mark G Roback; Christina Sophia Albott; Melinda Westlund Schreiner; Yanan Ren; Lynn E Eberly; Patricia Carstedt; Ali Samikoglu; Meredith Gunlicks-Stoessel; Kristina Reigstad; Nathan Horek; Susannah Tye; Kelvin O Lim; Bonnie Klimes-Dougan
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-07-13       Impact factor: 2.576

Review 8.  Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.

Authors:  John H Krystal; Gerard Sanacora; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2013-06-15       Impact factor: 13.382

9.  Novel Glutamatergic Treatments for Severe Mood Disorders.

Authors:  Minkyung Park; Mark J Niciu; Carlos A Zarate
Journal:  Curr Behav Neurosci Rep       Date:  2015-10-09

10.  The role of ketamine in treatment-resistant depression: a systematic review.

Authors:  Gianluca Serafini; Robert H Howland; Fabiana Rovedi; Paolo Girardi; Mario Amore
Journal:  Curr Neuropharmacol       Date:  2014-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.